STAAR Surgical (NASDAQ:STAA) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of STAAR Surgical (NASDAQ:STAA) from a sell rating to a hold rating in a report published on Saturday morning, BidAskClub reports.

Several other equities research analysts also recently issued reports on STAA. Zacks Investment Research downgraded shares of STAAR Surgical from a buy rating to a hold rating in a research note on Thursday, January 9th. BTIG Research started coverage on shares of STAAR Surgical in a research note on Wednesday, December 4th. They issued a buy rating and a $46.00 price objective on the stock. Stephens restated a buy rating and issued a $56.00 price objective on shares of STAAR Surgical in a research note on Thursday, January 2nd. ValuEngine downgraded shares of STAAR Surgical from a buy rating to a hold rating in a research note on Tuesday, December 10th. Finally, Canaccord Genuity raised their price objective on shares of STAAR Surgical from $40.00 to $45.00 and gave the stock a buy rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $44.25.

Shares of STAA stock opened at $40.25 on Friday. STAAR Surgical has a 12 month low of $21.70 and a 12 month high of $41.65. The company has a quick ratio of 4.96, a current ratio of 5.50 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $36.61 and its two-hundred day moving average is $32.04. The company has a market cap of $1.73 billion, a PE ratio of 143.75 and a beta of 2.34.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. STAAR Surgical had a return on equity of 13.84% and a net margin of 6.15%. The company had revenue of $39.06 million for the quarter, compared to the consensus estimate of $37.50 million. As a group, equities analysts expect that STAAR Surgical will post 0.25 EPS for the current fiscal year.

In other STAAR Surgical news, CFO Deborah J. Andrews sold 4,167 shares of STAAR Surgical stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $34.68, for a total transaction of $144,511.56. Following the sale, the chief financial officer now owns 32,101 shares in the company, valued at $1,113,262.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott D. Barnes sold 1,583 shares of STAAR Surgical stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $34.93, for a total transaction of $55,294.19. Following the sale, the insider now owns 11,032 shares in the company, valued at approximately $385,347.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,341 shares of company stock worth $2,635,130. 4.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System boosted its stake in STAAR Surgical by 1.2% during the third quarter. California State Teachers Retirement System now owns 69,261 shares of the medical instruments supplier’s stock worth $1,786,000 after buying an additional 836 shares in the last quarter. Royal Bank of Canada boosted its stake in STAAR Surgical by 483.3% during the second quarter. Royal Bank of Canada now owns 1,190 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 986 shares in the last quarter. United Services Automobile Association boosted its stake in STAAR Surgical by 12.7% during the second quarter. United Services Automobile Association now owns 9,848 shares of the medical instruments supplier’s stock worth $289,000 after buying an additional 1,113 shares in the last quarter. Bank of Montreal Can boosted its stake in STAAR Surgical by 64.4% during the second quarter. Bank of Montreal Can now owns 3,704 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 1,451 shares in the last quarter. Finally, Morgan Stanley boosted its stake in STAAR Surgical by 10.9% during the second quarter. Morgan Stanley now owns 20,589 shares of the medical instruments supplier’s stock worth $605,000 after buying an additional 2,029 shares in the last quarter. Hedge funds and other institutional investors own 92.51% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Recommended Story: Closed-End Mutual Funds

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.